
BIOLASE BIOL
Quarterly report 2024-Q3
added 11-07-2024
BIOLASE Accounts Payables 2011-2026 | BIOL
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables BIOLASE
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.06 M | 5.79 M | 3.31 M | 2.65 M | 5.33 M | 5.95 M | 5.11 M | 9.12 M | 5.96 M | 8.36 M | 8.56 M | 7.66 M | 7.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.12 M | 2.65 M | 6.28 M |
Quarterly Accounts Payables BIOLASE
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 M | 5.49 M | 4.92 M | 6.06 M | 7.18 M | 6.31 M | 7.54 M | 5.79 M | 4.97 M | 4.96 M | 4.64 M | 3.31 M | 3.6 M | 3.5 M | 3.07 M | 2.65 M | 2.65 M | 2.65 M | 2.65 M | 5.33 M | 5.33 M | 5.33 M | 5.33 M | 5.95 M | 5.95 M | 5.95 M | 5.95 M | 5.11 M | 5.11 M | 5.11 M | 5.11 M | 9.12 M | 9.12 M | 9.12 M | 9.12 M | 5.96 M | 5.96 M | 5.96 M | 5.96 M | 8.36 M | 8.36 M | 8.36 M | 8.36 M | 8.56 M | 8.56 M | 8.56 M | 8.56 M | 7.66 M | 7.66 M | 7.66 M | 7.66 M | 7.8 M | 7.8 M | 7.8 M | 7.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.12 M | 2.65 M | 6.19 M |
Accounts Payables of other stocks in the Medical devices industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
2.76 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
1.21 M | - | 3.58 % | $ 2.21 M | ||
|
Alphatec Holdings
ATEC
|
40.9 M | $ 12.42 | -4.46 % | $ 1.86 B | ||
|
Axonics Modulation Technologies
AXNX
|
9.07 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
2.28 M | - | 1.37 % | $ 20.5 M | ||
|
Bruker Corporation
BRKR
|
234 M | $ 38.55 | 0.13 % | $ 5.74 K | ||
|
Cognyte Software Ltd.
CGNT
|
25.2 M | $ 8.31 | 1.4 % | $ 597 M | ||
|
Conformis
CFMS
|
4.16 M | - | - | $ 16.4 M | ||
|
Cutera
CUTR
|
19.8 M | - | -10.19 % | $ 1.99 M | ||
|
AdaptHealth Corp.
AHCO
|
352 M | $ 9.61 | -0.62 % | $ 1.3 B | ||
|
Apollo Endosurgery
APEN
|
7.42 M | - | - | $ 475 M | ||
|
Dynatronics Corporation
DYNT
|
3.4 M | - | 14.99 % | $ 929 K | ||
|
Electromed
ELMD
|
2.67 M | $ 24.26 | -0.12 % | $ 205 M | ||
|
Cardiovascular Systems
CSII
|
14.4 M | - | 0.15 % | $ 844 M | ||
|
CONMED Corporation
CNMD
|
93.6 M | $ 41.66 | -3.09 % | $ 1.29 B | ||
|
EDAP TMS S.A.
EDAP
|
5.71 M | $ 4.19 | -1.41 % | $ 156 M | ||
|
Avinger
AVGR
|
777 K | - | -20.74 % | $ 369 K | ||
|
AxoGen
AXGN
|
2.89 M | $ 29.15 | -0.24 % | $ 1.34 B | ||
|
Apyx Medical Corporation
APYX
|
2.71 M | $ 3.27 | -0.82 % | $ 113 M | ||
|
Eargo
EAR
|
6.5 M | - | - | $ 10.2 M | ||
|
Second Sight Medical Products
EYES
|
817 K | - | -0.97 % | $ 54.4 M | ||
|
FONAR Corporation
FONR
|
1.55 M | $ 18.59 | 0.3 % | $ 122 M | ||
|
Accuray Incorporated
ARAY
|
34 M | $ 0.5 | -4.78 % | $ 51.4 M | ||
|
Cytosorbents Corporation
CTSO
|
3.34 M | $ 0.81 | 1.91 % | $ 44.1 M | ||
|
Align Technology
ALGN
|
109 M | $ 175.78 | -3.51 % | $ 13.2 B | ||
|
Butterfly Network
BFLY
|
4.25 M | $ 3.7 | -8.31 % | $ 783 M | ||
|
Abbott Laboratories
ABT
|
4.24 B | $ 110.91 | -1.94 % | $ 193 B | ||
|
InMode Ltd.
INMD
|
17.9 M | $ 13.49 | -0.55 % | $ 872 M | ||
|
Boston Scientific Corporation
BSX
|
1.14 B | $ 72.61 | 0.55 % | $ 107 B | ||
|
IRIDEX Corporation
IRIX
|
4.5 M | $ 1.4 | -0.71 % | $ 22.6 M | ||
|
IRadimed Corporation
IRMD
|
1.9 M | $ 100.27 | -4.6 % | $ 1.27 B | ||
|
Helius Medical Technologies
HSDT
|
531 K | $ 2.26 | -2.16 % | $ 1.37 M | ||
|
OrthoPediatrics Corp.
KIDS
|
18.8 M | $ 17.55 | -5.03 % | $ 412 M | ||
|
Edwards Lifesciences Corporation
EW
|
228 M | $ 83.7 | -1.78 % | $ 48.9 B | ||
|
Pulmonx Corporation
LUNG
|
3.83 M | $ 1.61 | 12.07 % | $ 63 M | ||
|
Inogen
INGN
|
20.3 M | $ 6.53 | 3.41 % | $ 174 M | ||
|
LivaNova PLC
LIVN
|
97.2 M | $ 64.29 | -1.49 % | $ 3.51 B |